Tools for Characterization of *Escherichia coli* Genes of Unknown Function

Christophe Merlin, Sean McAteer, and Millicent Masters*

Institute for Cell and Molecular Biology, University of Edinburgh, Edinburgh EH9 3JR, Scotland

Despite the power of sequencing and of emerging high-throughput technologies to collect data rapidly, the definitive functional characterization of unknown genes still requires biochemical and genetic analysis in case-by-case studies. This often involves the deletion of target genes and phenotypic characterization of the deletants. We describe here modifications of an existing deletion method which facilitates the deletion process and enables convenient analysis of the expression properties of the target gene by replacing it with an FRT-*lacZ-aph-P*$_{lac}$-FRT cassette. The *lacZ* gene specifically reports the activity of the deleted gene and therefore allows the determination of the conditions under which it is actively expressed. The *aph* gene, encoding resistance to kanamycin, provides a selectable means of transducing a deleted locus between strains so that the deletion can be combined with other relevant mutations. The *lac* promoter helps to overcome possible polar effects on downstream genes within an operon. Because the cassette is flanked by two directly repeated FRT sites, the cassette can be excised by the Flp recombinase provided in *trans*. Removing the cassette leaves an in-frame deletion with a short scar which should not interfere with downstream expression. Replacements of *yacF*, *yacG*, *yacH*, *yacK* (*cueO*), *yacL*, *ruvA*, *ruvB*, *yabB*, and *yabC* made with the cassette were used to verify its properties.

Years were required to sequence the first bacterial genomes; with present technology, small genomes can be sequenced in days (although annotation and analysis is still a slow process). In addition, high-throughput techniques, such as microarrays for transcriptional analysis and recently developed chips for proteomic analysis, permit the acquisition of massive amounts of information in single, albeit complex to interpret, experiments. Despite the availability of these technologies, the fully annotated sequences of over 80 species of prokaryotes, and rapid and widely available software for protein sequence comparison and analysis, at least half of the open reading frames (ORFs) listed for each sequenced species correspond to genes of either hypothetical or unknown function. This is true even for so well studied an organism as the model bacterium *Escherichia coli* K-12, which has about 4,300 annotated genes. According to Serres et al. (18), about 1,250 ORFs have been assigned possible functions which await confirmation, but a further 850 still have entirely unknown functions. Since the genome was originally annotated in 1997, only about 4% of the genes have had definite functions assigned on the basis of experiment or very close homology with a gene of verified function.

A popular approach to the functional characterization of an uncharacterized gene is to delete its coding sequence from the genome and look for consequent phenotypic changes. Methods to precisely delete *E. coli* genes are based on promoting genetic exchange between an altered locus engineered in vitro and the target chromosomal locus. There are two classes of

method currently favored. The first employs linear DNA, which can be exchanged by a double crossover to replace the chromosomal target with engineered DNA in a single step (14). The most recent variant of this technique obviates the need for cloning altogether by using primers which need include no more than 50 bp of homology flanking the target gene to amplify a selective marker. The linear product is introduced by electroporation into a host expressing the lambda Red-Gam recombination system. Gam inhibits the RecBCD nuclease, which normally degrades linear DNA, and Red is able to mediate recombination between the very short regions of homology flanking the selective marker to replace the target gene with the engineered linear fragment (7, 20).

The second class of methods uses DNA circles, usually conditionally replicating plasmids (which are immune to exonuclease digestion), as delivery systems. The plasmids, which incorporate cloned DNA flanking the target, are forced to integrate into one of the homologous regions by selection for retention of a plasmid marker under restrictive conditions. Longer regions of homology, about 400 bp each, are required to achieve good rates of recombination using host enzymes. The later return of survivors to permissive conditions allows cointegrate resolution. Selection against the plasmid favors survivors in which allele exchange has occurred, and screening is used to identify them (8, 11). Another plasmid-based method has been described which uses a suicide plasmid carrying the desired target gene mutation and a unique recognition site for the meganuclease I-*Sce*I. When integrated into the chromosome, the plasmid is flanked by the wild-type target locus and the constructed replacement, which includes DNA homologous to the target. Provision of I-*Sce*I in *trans* will result in a double-strand cut, which will stimulate recombination between the alleles, and the engineered version can be selected (16).

The first method, when successful, can be very fast, as no

* Corresponding author. Mailing address: Institute of Cell and Molecular Biology, University of Edinburgh, Darwin Building, King's Buildings, Mayfield Rd., Edinburgh EH9 3JR, Scotland. Phone: 44 (0)131 650 5355. Fax: 44 (0)131 650 8650. E-mail: M.Masters @ed.ac.uk.

TABLE 1. *E. coli* strains and plasmids

Name	Genotype or characteristics	Source or references
E. coli strains		
DH5α	φ80*lacZ*ΔM15 *recA1 endA1 gyrA96 thi-1 hsdR17*(r$_K^-$ m$_K^+$) *supE44 relA1 deoR* Δ(*lacZYA-argF*)*U169*	17
MG1655	Sequenced λ$^-$ and F$^-$ derivative of K-12	3
TOP10	F$^-$ *mcrA* Δ(*mrr-hsdRMS-mcrBC*) (φ80*lacZ*ΔM15 Δ*lacX74 deoR recA1 araD139* Δ(*ara-leu*)*7697 galU galK rpsL endA1 nupG*	Invitrogen
TP8503	Δ(*lac-proB*) *leu thi-1 supE42 fhuA*	12
XL1Blue	*recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac* [F′ *proAB lac1*�q*Z*ΔM15 Tn*10*]	Stratagene
Plasmids		
pBN	pBR322 Ω [*Eco*RI-*Hin*dIII: 79 bp, polylinker of pNUB193]	This study
pBNLC	pBN Ω [*Sma*I-*Sma*I: 4,725 bp, *lacZ-lacY′-cat* from pRS551-SL]	This study
pBNLCPS	pBNLC Ω [*Stu*I-*Stu*I: 242 bp, P$_{lac}$ promoter]	This study
pBR322	Ap^r Tc^r; cloning vector	GenBank no. J01749
pBR325	Ap^r Tc^r Cm^r; cloning vector	GenBank no. L08855
pCP20	Ap^r Cm^r *repA*(Ts); pSC101-based vector expressing the Flp recombinase	5
pKD4	Ap^r Km^r *oriR* plasmid containing an FRT-*aph*-FRT cassette	7
pKO3	Cm^r; pSC101-based vector; *repA*(Ts) with a *sacB* conferring sucrose sensitivity	11
pNUB193	pUC19 derivative with additional restriction sites in its polylinker	New England BioLabs Inc.
pRS551	Ap^r Km^r *lacZ*; operon fusion vector	19
pRS551-SL	Same as pRS551 but without tryptophan terminator upstream of *lacZ*	This study
pSLO3	Ap^r *lacZ*; promoter cloning vector	10
pTOF1	pUC18 Ω [*Eco*RI-*Hin*dIII: 162 bp, *Not*I-FRT-*Sma*I-FRT-*Not*I]; Ap^r	This study
pTOF2 and -3	pTOF1 Ω [*Hin*cII-*Hin*cII: 1,252 bp, *aph* gene from pUC4K]; Ap^r Km^r	This study
pTOF20	pTOF1 Ω [*Sma*I-*Sma*I: 4,967 bp, *LacZ-cat-P$_{lac}$* of pBNLCS]; Ap^r Cm^r	This study
pTOF24	pK03 Ω [*Hin*cII-*Hin*cII: 1,252 bp, *aph* from pUC4K]; Cm^r Km^r Ts Suc^s	This study
pTOF25	pKO3 Ω [*Bam*HI-*Bam*HI: 1,264 bp, *aph* from pUC4K]; Cm^r Km^r Ts Suc^s	This study
pTOF27	Site-directed mutagenesis of pTOF20 adding a *Sna*BI site in *lacY*; Ap^r Cm^r	This study
pTOF29 and -30	pTOF27 Ω [*Hin*cII-*Hin*cII: 1,252 bp, *aph* gene from pUC4K]; Ap^r Km^r	This study
pTOF60	Site directed mutagenesis of pTOF27 adding a *Sna*BI site upstream of P$_{lac}$; Ap^r Cm^r	This study
pTOF61	Site-directed mutagenesis of pBR322 adding a *Not*I site in *tet*; Ap^r	This study
pTOF70	pTOF61 Ω [*Not*I-*Not*I: 5,114 bp, FRT-*lacZ-cat-P$_{lac}$*-FRT from pTOF60]; Ap^r Cm^r	This study
pTOF72 and -73	pTOF70 Ω [*Hin*cII-*Hin*cII: 1,252 bp, *aph* gene from pUC4K] Ap^r Km^r	This study
pUC4K	Ap^r Km^r; cloning vector	GenBank no. X06404
pUC18	Ap^r; cloning vector	GenBank no. L08752
pUC19	Ap^r; cloning vector	GenBank no. M77789

cloning steps are required. However, the length of the replacing sequence is limited by the need to accurately amplify it, and acceptable rates of recombination and replacement are not necessarily easy to achieve. Methods of the second type have at least one cloning step (plus a second if a selective marker is used) and therefore require more time to complete, typically several weeks. However, a large replacement can be made without difficulty. Since each step of the procedure can be monitored for success and the number of successful replacements is expected to be high, it is easy to judge whether failures have a technical or biological basis.

Here, we report improvements and useful modifications made to the method described by Link et al. (11) in which a low-copy-number temperature-sensitive plasmid vector, pKO3, was used. First, we have modified the replacement vector to facilitate the cloning procedure. Second, we have constructed a series of removable cassettes that can be used to replace a target gene and have demonstrated that they work as designed. Each cassette is flanked by two FRT sites, in direct orientation, which allows removal of the cassette by the Flp site-specific recombinase provided in *trans*. Our design includes a full-length promoter-free *lacZ* reporter gene to allow measure-

ment of target gene expression under a variety of conditions. To avoid transcriptional polar effects, a controllable P$_{lac}$ promoter has been added at the distal end of the cassette to maintain transcription of downstream genes. Although the P$_{lac}$ promoter will not compensate for any translational polarity which may be a feature of the operon under study, translational polarity should be restored upon cassette removal. Compared to the original pKO3 method (11), the use of a selectable reporter cassette simplifies the recovery of allele replacement mutants and extends the range of possible phenotypic studies to include gene expression measurement.

MATERIALS AND METHODS

Strains, plasmids, and media. The strains and plasmids used in this study are described in Table 1. All strains were grown in Luria-Bertani (LB) medium (Difco tryptone, 1%; Beta Lab yeast extract, 0.5%; NaCl, 1%) with appropriate selection and growth temperatures. Kanamycin (Km), ampicillin (Ap), and chloramphenicol (Cm) were at concentrations of 50, 100, and 20 μg/ml, respectively. For counterselection of *sacB* plasmids, sucrose was added to a final concentration of 5%. Recovery of transformants prior to selection was done either in LB medium supplemented with glucose (0.36%) or in the SOC medium provided by the manufacturer in the case of TOP10 transformation (Invitrogen).

TABLE 2. Primers used

Name	Restriction site(s)	Sequence[a]
Primers for engineering FRT cassettes		
FRTupNotI	*Eco*RI, *Not*I	GgaATTcTGTAGGCTGGAGCgGCcgCGAAGTTCC
FRTdownSmaI	*Sma*I	GAGTGCTTGCGGCAGCGcccGGGGATCTTG
FRTupSmaI	*Sma*I	TTGTGTAGcCcGGgGCTGCTTCGAAGTTCC
FRTdownNotI	*Not*I, *Hin*dIII	CCTGAaaGCTTGCGGCcGCGTGAGGGGATCTTG
MutLCP1	*Sna*BI	CGCGTAAGGAAATCCATTACGTACTATTTAAAAAACACAAAC
MutLCP2	*Sna*BI	GTTTGTGTTTTTTAAATAGTACgTAATGGATTTCCTTACGCG
MutLCP3	*Sna*BI	CGTCGCCCAATACGtAAACCGCCTCTCCC
MutLCP4	*Sna*BI	GGGAGAGGCGGTTTaCGTAttGGGCGACG
MutPBR1	*Not*I	CCGACCGCTTTGGCgGCCGCCCAGTCCTGC
MutPBR2	*Not*I	GCAGGACTGGGCGGCcGCCAAAGCGGTCGG
NEWCAT-UP	*Ecl*136II	GGCGgAgcTcTTGAGTTATCGAGATTTTCAGGAGC
NEWCAT-DWN	*Sma*I, *Stu*I	TTATTCccGgGTAGCACtAGGCcTTTAAGGGCACC
PLAC-1	*Stu*I	CAGGCATGCAgGCcTtGCGTAATC
PLAC-3	*Stu*I	GAGGAgGCCctgAcgtCGCCCAATAC
Replacement primers[b]		
ruvA deletion		
CiRuvA	*Not*I	ccgttccaagcggccgcaagagcgGTGAGCAAAATCGCTCGCCCTGAC
CoRuvA	*Sal*I	aaaaagtcgacAACAGCACGTCATGCGGTTCAAGG
NiRuvA	*Not*I	cgctcttgcggccgcttggaacgTCTGAGTCTGCCTATCACATGACG
NoRuvA	*Pst*I	aaaaactgcagGTGATTACTCCAGCAATTTGATGC
ruvB deletion		
CiRuvB4	*Not*I	gttctgcagcggccgcgaattccgCCGCCAGAAATGCCGTAAGTC
CoRuvB2	*Sal*I	cgcacgcatgtcgacCGCAATTTGCTGTCAATGACGATAAG
NiRuvB3	*Not*I	cggaattcgcggccgctgcagaacCATCCTTTACCTCATAACGCGGC
NoRuvB3	*Sma*I	aaggaaaaaagcccgggcAAGCGGGTCAGGAAGCG
yacH deletion		
CiYacH	*Not*I	ccgttccaagcggccgcaagagcgCGTGGAGCAAGAAGACTGGAAAGG
CoYacH	*Sal*I	aaaaagtcgacATACCGAACCAGAAGTTGCATGGG
NiYacH	*Not*I	cgctcttgcggccgcttggaacggGCAAATTAGCGCCAGCACATGGGG
NoYacH	*Pst*I	aaaaactgcagTACGGTATTCTTCTAGCACGACGG
yacL deletion		
CiYacL	*Not*I	ccgttccaagcggccgcaagagcgGTCGTGGCGGCTTACCGCAATTTC
CoYacL	*Sal*I	aaaaagtcgacCAGCTTGAGTCCGATATCGTAACC
NiYacL	*Not*I	cgctcttgcggccgcttggaacggCACTTCATGCCCCATGGACATACG
NoYacL	*Pst*I	aaaaactgcagGCGAATGTCTTCCTGGCTTCTGCG
yacK deletion		
CiYacK	*Not*I	ccgttccaagcggccgcaagagcgGAAGATACGGGGATGATGTTAGGG
CoYacK	*Sal*I	aaaaagtcgacTCGCCGCTACGGCAGATAACTACC
NiYacK	*Not*I	cgctcttgcggccgcttggaacggCGGCAAAGCCGAAGCCACACCCAG
NoYacK	*Pst*I	aaaaactgcagAGGTGTCGTAATTACTGAGGTCCC
yacF deletion		
CiYacF	*Not*I	ccgttccaagcggccgcaagagcgTTTGCCATTCGTTTTATGCCGCTG
CoYacF	*Sal*I	aaaaagtcgacGGCGCGTCTTATCAGGCCTAAAGG
NiYacF	*Not*I	cgctcttgcggccgcttggaacggAAACTCAATGCGCAGCCATGTACG
NoYacF	*Pst*I	aaaaactgcagCACCAGATCCAGCAAGCTACTTCC
yacG deletion		
CiYacG	*Not*I	ccgttccaagcggccgcaagagcgGAAGAACCAAAGCAGTGACATTTG
CoYacG	*Sal*I	aaaaagtcgacCTGGAATATGAATTCCCGGACAGG
NiYacG	*Not*I	cgctcttgcggccgcttggaacggCACCACCGTTTTCCCGCAGGTTGG
NoYacG	*Pst*I	aaaaactgcagGCAGCTTTGATTTACCTACATTGC
yabB deletion		
CiYabB1	*Not*I	ccgttccaagcggccgcaagagcgCTGTCGAGCATGAACCCGGTTGAG
CoYabB	*Sal*I	aaaaagtcgacCGGGTTGGGTCCATACGCATGTCC
NiYabB1	*Not*I	cgctcttgcggccgcttggaacggGTCGAGATTGACTAACGTTGCTCC
NoYabB	*Sma*I	aaaaacccgggTGTTACATGCGGCGATGAATTGCC
yabC deletion		
CiYabC	*Not*I	ccgttccaagcggccgcaagagcgGGGTTACCGATGACTGAAGAGCAG
CoYabC	*Sal*I	aaaaagtcgacAGCGCATTCTCTTCAAGGATCAGG
NiYabC	*Not*I	cgctcttgcggccgcttggaacggCCCATCAATGTAGATGCCATCAGG
NoYabC	*Sma*I	aaaaacccgggCACCATTGACATTTATCACCCGTG

[a] Restriction sites are underlined; sequences altered with respect to the template are in lowercase.
[b] For the replacement primers, the prefixes C and N indicate the 5′ and 3′ ends, respectively, of the deleted genes, while i and o stand for inner (outward-pointing) and outer (inward-pointing) primers.

FIG. 1. Construction of the *lacZ-cat-P_{lac}* and *lacZ-aph-P_{lac}* reporter cassettes. The constructions were started with pRS551 (top left) and the amplification of FRT sites (bottom left). The large shaded arrows indicate the path of construction, which is described in detail in the text. T marks the weak transcription terminator in *trp*. Restriction sites are indicated with one or two letters: B, *Bam*HI; Ec, *Eco*RI; E, Ecl136; Hc, *Hin*cII; H, *Hin*dIII; N, *Not*I; Sa, *Sac*I; Sm, *Sma*I; Sb, *Sna*BI; and St, *Stu*I. The short solid arrows mark FRT sites. Intact genes and their directions of transcription are shown as long solid arrows on the DNA. Untranscribed gene fragments are shown as solid bars. Vertical dotted reference lines connect points with the same DNA sequence. All named plasmids are further described in Table 1.

DNA manipulation. For plasmid DNA purification, genomic DNA preparation, DNA cleaning, DNA gel extraction, and DNA site-directed mutagenesis, we used the Wizard Plus SV Minipreps kit (Promega), the Quantum Prep AquaPure genomic DNA isolation kit (Bio-Rad), the QIAquick PCR purification kit (Qiagen), the QIAquick gel extraction kit (Qiagen), and the QuikChange site-directed mutagenesis kit (Stratagene).

Crossover PCR (9) and analytical PCR were carried out on OmniGene and PCR Sprint cyclers (Hybaid) using *Pfu* DNA polymerase (Promega) and *Taq* DNA polymerase (Promega), respectively, according to the manufacturers' recommendations. The primers used in this study were purchased from either Sigma-Genosys or MWG-Biotech and are listed in Table 2. Restriction endonucleases were purchased from Roche, Promega, or New England BioLabs Inc.

Ligations were carried out using standard procedures (17). Prior to ligation with T4 DNA ligase (Roche), vectors were dephosphorylated with calf alkaline phosphatase (Roche), and both vector and insert DNA were purified using a QIAquick PCR purification kit.

Transformation of bacteria with engineered plasmid DNA was done using a classical CaCl₂ preparation unless high-efficiency transformation was needed, in which case electroporation was employed (17). Recombinant DNA was recovered in DH5α or, after site-directed mutagenesis, in XL1Blue. After the FRT cassette cloning step, recombinant DNA was recovered in TOP10 using One Shot TOP10 competent cells (Invitrogen).

Construction of lacZ-cat-P_{lac} reporter cassette. The modules of the *lacZ-cat-P_{lac}* cassette were assembled in several steps (Fig. 1). First, pRS551 (19) was reconstituted with a *lacZ* gene lacking the upstream *trp* transcriptional termina-

tor to create pRS551-SL. This was done by replacing the 2,453-bp *Bam*HI-*Sac*I fragment carrying the 5′ end of *lacZ* with the corresponding terminator-free *Bam*HI-*Sac*I fragment of pSLO3 (10). In a second step, *cat* was PCR amplified from pBR325 using the primers NEWCAT-UP and NEWCAT-DWN to engineer an upstream *Ecl*136II site and downstream *Stu*I and *Sma*I sites, respectively. The 762-bp PCR product was cut with *Ecl*136II and *Sma*I and cloned into the unique *Sma*I site of pUC18. The *cat* gene was cut from pUC18 using *Ecl*136II and *Hin*cII and cloned into the *Sna*BI site (in *lacY*) of pRS551-SL. In a third step, the *lacZ-cat* module was cut from pRS551-SL with *Sma*I and cloned into the unique *Sma*I site of pBN to produce the plasmid pBNLC. Finally, *P_{lac}* was PCR amplified from pUC19 using the primers PLAC-1 and PLAC-3 designed to flank the PCR product with *Stu*I restriction sites. The PCR product was cut with *Stu*I and cloned into the unique *Stu*I site downstream of the *cat* gene on plasmid pBNLC. The resulting plasmid, pBNLCPS, was later used to deliver the *lacZ-cat-P_{lac}* cassette.

Construction of a set of FRT cassettes. Two directly repeated FRT sites were combined in an initial construct (Fig. 1, bottom left). The sites were amplified from pKD4 using *Pfu* turbo (Stratagene), and two sets of primers were designed to flank the FRT product with either *Eco*RI-*Not*I and *Sma*I (primers FRTupNotI and FRTdownSmaI) or *Sma*I and *Not*I-*Hin*dIII (primers FRTupSmaI and FRTdownNotI). The first PCR product was cut with *Eco*RI and *Xma*I, the second was cut with *Xma*I and *Hin*dIII, and the products were purified and ligated to *Eco*RI- and *Hin*dIII-cut pUC18 in a three-molecule cloning. The recombinant plasmid pTOF1 was recovered after electroporation of DH5α, and the 162-bp insert sequence was confirmed by sequencing. The FK1 and FK2 cassettes (Fig. 2) were

FIG. 2. FRT cassettes constructed and used in this work. The small hatched rectangles at the ends of each cassette represent FRT sites. Genes and their directions of transcription are indicated by open arrows. The constructions are described in the text and in the legend to Fig. 1.

made by cloning the 1,252-bp *Hin*cII fragment of pUC4K, containing the *aph* gene (specifying kanamycin resistance), into pTOF1 at the unique *Sma*I site located between the two FRT sites. The recombinant plasmids pTOF2 and pTOF3, containing the *aph* gene in different orientations, were recovered in DH5α. The FLCP1 cassette was constructed by cloning the 4,961-bp *Sma*I fragment of pBNLCPS, containing the *lacZ-cat-P_{lac}* module, into *Sma*I-cut pTOF1. The resulting recombinant plasmid, pTOF20, was mutagenized (primers MutLCP1 and MutLCP2) to generate an *Sna*BI site overlapping the first codon of *lacY*. The resulting plasmid, pTOF27, was cut with *Sna*BI and *Stu*I, and the excised *lacY'-cat-P_{lac}* module was replaced with the 1,252-bp *Hin*cII fragment containing the Km^r determinant of pUC4K. pTOF29 and pTOF30, bearing the cassettes FLK1 and FLK2, respectively, contain the *aph* gene in different orientations. pTOF27 was further mutagenized to introduce a new *Sna*BI site upstream of *P_{lac}* using the primers MutLCP-3 and MutLCP-4. The resulting plasmid, pTOF60, contained two mutagenized *P_{lac}* sequences (one originating from pUC18 and the other originating from the FLCP cassette). We separated them by transferring the 5,114-bp *Not*I fragment of pTOF60 containing the mutagenized FLCP cassette into the unique *Not*I site of pTOF61, a pBR322 plasmid with a *Not*I site introduced into the tetracycline resistance gene. This pBR322 derivative, pTOF70, contains a 1,548-bp *lacY'-cat* module flanked by two *Sna*BI sites, which was replaced by the 1,252-bp *Hin*cII fragment of pUC4K to generate the FLKP1 and FLKP2 cassettes of plasmids pTOF72 and pTOF73, respectively.

Construction of replacement vectors. The two replacement vectors, pTOF24 and pTOF25, derive from plasmid pKO3 (11). The three essential features of pKO3 are maintained in pTOF24 and pTOF25. The plasmids are unable to replicate at temperatures above 42°C, as they encode a temperature-sensitive replication protein (*repAts*). In addition, they contain a Cm^r (*cat*) marker for selection and a counterselective marker originating from *Bacillus subtilis*, *sacB*. The *sacB* gene encodes a levan sucrase, which catalyzes sucrose hydrolysis and levan extension. In *E. coli*, the products of this reaction are toxic, and the cells are sucrose sensitive. To construct pTOF24 and pTOF25, the short polylinker, *Sma*I-*Not*I-*Bam*HI-*Not*I-*Sal*I, of pKO3 was modified by cloning the 1,252-bp *Hin*cII fragment containing the Km^r determinant of pUC4K into the unique *Sma*I site of the pKO3 polylinker. Although the *Sma*I site was lost, a *Pst*I site, provided by the insert, was added. This new vector, pTOF24, is used for *Sal*I-*Pst*I cloning. pTOF25 was obtained by cloning the 1,264-bp *Bam*HI fragment containing the Km^r determinant of pUC4K into the unique *Bam*HI site of pKO3; pTOF25 is used for *Sal*I-*Sma*I cloning. Cloning into pTOF24 or pTOF25, using *Sal*I-*Pst*I or *Sal*I-*Sma*I, leads to a screenable loss of Km^r.

Availability of material. All plasmids, FRT cassettes, constructs, and strains, as well as sequence or general information concerning the materials used to per-

form the genetic alterations described in this article, are available by contacting the authors.

RESULTS

An improved gene replacement procedure. Precise deletions of *E. coli* ORFs were performed using a method based on that described by Link et al. (11). The step-by-step procedure and the sites of annealing of the primers used in this study are described in Fig. 3 and 4, respectively. The replacement procedure starts with the in vitro construction of a deletion cassette using a two-step crossover PCR protocol (9). In the first step, ~400-bp segments corresponding to the regions flanking the locus or gene targeted (arms) are independently amplified using the pairs of primers No-Ni and Ci-Co (Fig. 4A). N (N-terminal) and C (C-terminal) primers anneal upstream and downstream of the target gene, respectively, while "i" (inside) and "o" (outside) indicate whether the priming site is closer to or further from the target gene. The Ni and Ci inside primers are designed to leave the ends of the targeted genes intact in order to retain the original translational signals in the final construct. In addition, Ni and Ci contain 24-nucleotide-long 5′ tails with complementary sequences. Each tail also contains a *Not*I restriction site for later FRT cassette insertion. In a second PCR step, the previously amplified arms are fused together using the complementary ends (provided by Ni and Ci tails). Typically, 1 μl of each arm PCR mixture is used as a template, and the fusion product is amplified with No and Co primers (Fig. 4B). In addition to their priming sequences, No and Co primers each contain an 11-nucleotide tail providing convenient restriction sites for cloning (Table 2).

The PCR fusion product is cloned in one of the two pKO3-modified replacement vectors, pTOF24 or pTOF25, using a *Pst*I-*Sal*I or an *Sma*I-*Sal*I restriction strategy, respectively. Recombinant plasmids are recovered by transformation with selection on LB-chloramphenicol agar plates. In recombinants, the Km^r gene in the vector is replaced by the PCR fusion product and can be identified by Km^s screening; this is much simpler than the PCR screening required when using pKO3 (11). Finally, one of the FRT cassettes is cloned into the unique *Not*I restriction site at the junction of the fused PCR arms, and recombinant plasmids are recovered by transformation with selection on LB-chloramphenicol-kanamycin plates (Km^r is reestablished by cloning the FRT cassette).

Next, a Δ*lac* strain is transformed with the construct and allele replacement is started by streaking transformants on LB-chloramphenicol-kanamycin plates at 42°C. The antibiotics maintain selection for both plasmid and cassette, while the elevated temperature prevents autonomous replication of the plasmid. Thus, only integrants resulting from a homologous recombination between one of the arms of homology and the corresponding wild-type locus survive. Integrants are recognized as a small number of large colonies on a background of microcolonies. One integrant is repurified on the same medium at 42°C, and selective pressure is released by overnight culture at 30°C in LB medium, allowing the cointegrate to resolve by means of a second homologous recombination. Serial dilutions are plated on LB-sucrose-kanamycin plates at 37°C. Sucrose kills bacteria containing a functional *sacB* gene, either in the chromosome or on an autonomously replicating

plasmid, while kanamycin selects those retaining the cassette, indicating allele replacement. The frequencies of Km^r sucrose-resistant (Suc^r) colonies are quite variable from one experiment to another, but generally the colony counts on LB-kanamycin-sucrose and LB-kanamycin (or LB) are similar. This suggests that (i) the cointegrate is not stable and is quickly resolved when selective pressure is withdrawn and (ii) the plasmid is often lost during excision. When an attempt is made to replace an essential gene, the frequency of Km^r Suc^r colonies falls dramatically by several orders of magnitude. In the method of Link et al. (11), no selective cassette was used for replacement and therefore the Suc^r Cm^s bacteria isolated at the end of the replacement process might either be parent-like (if both insertion and resolution take place in the same arm) or deletants (if insertion and resolution take place in different arms). At this step, Suc^r bacteria which still retain plasmid are frequently isolated. Therefore, plasmid loss must be confirmed by screening survivors for the loss of Cm^r. In our hands, 3 to 100% of Km^r Suc^r survivors are Cm^s, with an average of 50%. It is not known whether plasmid-retaining, Suc^r colonies have a mutated *sacB* gene or whether sucrose toxicity is not lethal in some SacB$^+$ bacteria. Screening bacteria isolated without sucrose counterselection at the excision step, however, reduces the recovery of replacement clones by a factor of about 6.

At the end of the replacement process, Km^r Suc^r Cm^s colonies are analyzed by PCR to confirm that the cassette has replaced the wild-type locus. To do this, each junction between the cassette and the chromosome is amplified using a primer pair that primes (i) in the FRT cassette and facing outward (F1 or F2 primers) and (ii) in the flanking region facing toward the cassette (N$_{ext}$ or C$_{ext}$ primers) (Fig. 4C). It should be noted that N$_{ext}$ and C$_{ext}$ prime sequences that have not been cloned during the crossover PCR; otherwise, no distinction could be made between a gene replaced by an FRT cassette and the replacement plasmid containing the deletion cassette.

The cassette can be removed by site-specific recombination

FIG. 3. Gene replacement-deletion procedure. Wild-type genes are indicated by open boxes, while engineered sequences or plasmid genes are indicated by solid boxes. B, gene targeted for deletion; A and C, genes flanking B; *sacB*, levan sucrase gene, toxic in the presence of sucrose (Suc); *repAts*, temperature-sensitive system of replication; *cat* and *aph*, genes for Cm^r and Km^r, respectively. The steps of the procedure are as follows. (I) Construction of a deleted locus by crossover PCR. (II) Cloning of the crossover PCR product into pTOF24 or pTOF25 using the restriction sites (R1 and R3) provided by the outside primers (No and Co). The Km^r gene (*aph*) of the vector is replaced by the insert, and transformants are selected on LB-chloramphenicol medium at 30°C. (III) Cloning of an FRT cassette between the two arms of the crossover PCR insert into the unique *Not*I site initially provided by the internal primers Ni and Ci. Km^r is reestablished by the acquisition of the FRT cassette, and transformants are selected on LB-chloramphenicol-kanamycin plates at 30°C. (IV) First homologous recombination taking place after the introduction of the replacement plasmid in a Δ*lac* strain. (V) Selection of integrants on LB-kanamycin-chloramphenicol plates at 42°C. (VI) Excision of the plasmid after a second homologous recombination. Allele replacement and concomitant plasmid loss (×) are selected for on LB-kanamycin-sucrose plates at 37°C. (VII) Excision of the FRT cassette after transformation with pCP20. The circular form of the cassette does not replicate and disappears, while pCP20 can be cured at 42°C. The resulting strain is Km^s Cm^s Ap^s.

FIG. 4. Primer design for allele replacement construction and deletion confirmation. Intergenic chromosomal DNA is shown as solid, and FRT DNA is hatched. (A) Chromosomal DNA with genes A, B, and C. Primers No plus Ni and Co plus Ci were used to make arms for B deletion, using chromosomal DNA as a template. R1, R2, and R3 are restriction sites. (B) The arms made in panel A are annealed at R2, reamplified, and cloned. (C) An FRT cassette is inserted at R2, and the resultant replacement plasmid is introduced into the chromosome and resolved to make a replacement. Primers N_{ext} plus F1 and C_{ext} plus F2 are used to demonstrate that the replacement is correctly structured. (D) The chromosomal replacement after Flp-mediated cassette deletion. Arrows indicate primer position and direction.

FIG. 5. PCR amplifications of wild-type and deleted regions for five different ORFs. FRT cassette replacements were made for each of the genes *yacH*, *-L*, *-K*, *-G*, and the *-FG* pair. The FRT cassette was later deleted with FLp. Each lane labeled with an odd number shows amplified wild-type DNA, and the even-numbered lane to its right shows the corresponding deletion. Amplification in all cases used the appropriate N_{ext}-C_{ext} primer pair. DNA size standards (lanes L) are on both sides of the gel, with length in kilobases indicated on the right.

between the FRT sites flanking the cassette by providing the cognate Flp recombinase in *trans* with plasmid pCP20 (5). Plasmid pCP20 is a temperature-sensitive replicon with an *flp* gene under the control of a λ *c*I857 repressor. However, as already described, the basal expression of *flp* at 30°C is enough to catalyze extensive FRT recombination (5). Therefore, the Flp-catalyzed FRT cassette excision is simply carried out by transforming cassette-bearing clones with pCP20 and selecting transformants at 30°C on LB-chloramphenicol (or LB-ampicillin) medium. We find that 100% of the transformants have already lost the Km^r cassette marker at this step. Next, Km^s tansformants are cured of pCP20 by streaking them on LB plates at 42°C, and the loss of the plasmid is confirmed by a failure to grow on either chloramphenicol or ampicillin plates. Finally, cassette excision is checked by PCR using primers flanking the locus of interest; the PCR fragment obtained from a deleted locus will now have a reduced size compared to its corresponding wild type (Fig. 4D).

Gene replacement and cassette removal. The FRT cassettes have been successfully used to construct a number of deletions. The TP8503 genes *ruvA*, *ruvB*, *yacH*, *yacL*, and *yacK* have been

replaced by the cassette FLK2, and *yacF*, *yacG*, *yabB*, and *yabC* have been replaced by the cassette FLKP2. In all cases where it was attempted (*yacH* ⟨ ⟩ FLK2, *yacL* ⟨ ⟩ FLK2, *yacK* ⟨ ⟩ FLK2, *yacF* ⟨ ⟩ FLKP2, *yacG* ⟨ ⟩ FLKP2, *yabB* ⟨ ⟩ FLKP2, and *yabC* ⟨ ⟩ FLKP2), replacements were easily transduced to MG1655. P1 transduction can also be used for combining a replacement with a desired second mutation. All of the cassettes could be successfully removed by the Flp recombinase. Figure 5 shows PCR amplifications of wild-type loci and their deletion derivatives after the cassettes were removed. The same gene-specific outside primers were used for both the original gene and its deletion derivative. In all cases, the deletion is associated with a decrease in PCR fragment size as expected (although it is small in the case of the *yacG* deletion). It should be noted that the deletion process leaves a 93-nucleotide-long in-frame scar. When the deletion is correctly designed, the scar will not contain a stop codon, and the original translational signal of the truncated protein will remain functional.

Reporting the expression of the deleted gene. The FRT cassettes were engineered to increase the information that can be collected with a single deletion and replacement by using a cassette containing a *lacZ* reporter to replace the target gene. The efficacy of the reporter system was first tested with the *yacK* ⟨ ⟩ FLK2 replacement. The *yacK* gene, now known as *cueO*, has recently been characterized as encoding a multicopper oxidase, and its expression has been shown to be induced by copper (15). The replacement strain TP8503 *yacK* ⟨ ⟩ FLK2 was grown in LB medium to an optical density at 600 nm (OD$_{600}$) of 0.2, and an aliquot was treated with 0.5 mM CuSO$_4$. β-Galactosidase activity was assayed at regular inter-

FIG. 6. Use of *lacZ* to report expression of deleted genes. (A) An exponentially growing culture of TP8503 *yacK* ↔ FLK2 was divided in two (arrow), and one half was induced by addition of 0.5 mM CuSO₄. Samples of both cultures were collected for enzyme analysis. β-Galactosidase activity in the induced culture quickly reached levels about six times greater than that in the uninduced control. Solid bars, culture induced with 0.5 mM CuSO₄ (*Cu*); open bars, control culture. "X" indicates the OD$_{600}$, which was the same for both cultures. M.U., Miller units. (B) *ruvA* expression after SOS induction with mitomycin C. At an OD$_{600}$ of 0.1, cultures were divided and inducer was added to one of the cultures. At 100 min, samples were taken for assay. Lane 1, *ruv*⁺ control; lane 2, *ruvA* reporter replacement; lane 3, same as lane 2 but with the reporting cassette in the opposite orientation. Open bars, β-galactosidase activity control; solid bars, induced cultures.

vals during growth (13). Figure 6A shows that *yacK* expression increased by a factor of 5 to 6 following the addition of copper.

The FLK2 reporter was further tested in a *ruvA* replacement in strain TP8503. For this purpose, two different strains were constructed, one with *lacZ* placed so as to be transcribed by the *ruvA* promoter and the other with *lacZ* in reverse orientation (TP8503 *ruvA* ⟨ ⟩ FLK2$_{direct}$ and TP8503 *ruvA* ⟨ ⟩ FLK2$_{opposite}$). The expression of the *ruvAB* operon is normally repressed by LexA unless the SOS response is activated (2). Both TP8503 *ruvA* ⟨ ⟩ FLK2 strains were grown to an OD$_{600}$ of 0.1, and an aliquot was treated with 2 μg of mitomycin C/ml in order to induce an SOS response. β-Galactosidase activity was assayed 100 min after induction. Figure 6B shows that the reporter system of the cassette detects a threefold induction of *ruvA* expression from the cassette positioned so as to be transcribed from P_{ruvA}. With the FLK2 cassette in opposite orientation, no β-galactosidase activity was detected with or without mitomycin treatment, thus demonstrating the absence of background expression from the *lacZ* reporter.

The polar effect of the cassette can be reversed by removal in vivo. Because the FRT cassettes are expected to have a polar effect, gene replacement will be lethal if downstream genes in the same operon are essential for survival. To overcome this problem we constructed a set of cassettes with a distal P_{lac}-controllable promoter oriented outward (Fig. 2). Using FLKP2, we were able to delete the first two genes of the cell division gene cluster, *yabB* and *yabC*, in strain TP8503. Strain TP8503 has the entire *lac* region deleted, and the absence of *lacI* results in constitutive expression of P_{lac} from the cassette, thus providing downstream transcription without added IPTG (isopropyl-β-D-thiogalactopyranoside) in the TP8503 *yabB* ↔ FLKP2 and TP8503 *yabC* ⟨ ⟩ FLKP2 replacements. However, when these deletions were transduced to MG1655, progeny were not obtained unless the bacteria were cultivated in the

presence of 1 mM IPTG. IPTG was no longer required for growth after the FLKP2 cassette was removed by Flp recombinase. This demonstrates (i) that the polar effect of the cassette can be avoided by providing an active P_{lac} and (ii) that the 93-bp scar left after removal of the cassette does not prevent the expression of the downstream genes in an operon. The genes *yabB* and *yabC*, of unknown function, have been variously described as dispensable or essential (1, 4, 6). Our results confirm those of Dassain et al. (6) and show that neither ORF is needed provided that the cell division genes immediately downstream can be transcribed.

DISCUSSION

In this paper, we have described a revised gene deletion procedure based on the method reported by Link et al. (11). Several improvements have been made. First, the replacement vectors, pTOF24 and pTOF25, contain a Km^r stuffer fragment which facilitates the screening of recombinants after the crossover PCR cloning step. Second, we have developed and tested the set of FRT cassettes presented in this paper. The use of the FRT-*lacZ*-*aph*-P_{lac}-FRT cassette appears to provide advantages for the recovery of deletants and their analysis: (i) the reporter system allows the collection of expression data without further fusion construction and (ii) the P_{lac} promoter overcomes possible polar effects of the cassette.

The main disadvantage of the method is the length of time required (several weeks); the linear replacement methods, in contrast, can be very much faster. Our efforts are now focused on the development of a hybrid method consisting of two sequential linear replacements. In the first step, the gene targeted for deletion would be replaced with a short FRT cassette easily amplifiable by PCR, as already described (7, 20). The second step would be a second in vivo linear replacement of

the short cassette by a longer one containing *lacZ* and P_{lac}, using the fact that both cassettes have extensive sequence identity at their extremities.

Of the reporter cassettes, only FLK2 and FLKP2 have been used so far (Fig. 2). The other FRT cassettes were obtained during the construction process and are listed simply as additional materials that might be of use in particular cases. We do not know if the fact that *lacZ* and the *aph* transcription are convergent (in FLK1 and FLKP1) is likely to reduce *lacZ* expression. This would need to be tested by any user of these constructs. It should be noted, however, that although no terminator has been reported in the original sequence downstream of *aph*, this sequence contains several inverted repeats that might act to reduce transcription.

Finally, we are also investigating the possible use of the method in bacteria not related to *E. coli* for which genetic tools are lacking. In such bacteria, the pKO3-based vectors may well not replicate but could be used as suicide vectors. In outline, a replacement plasmid constructed in *E. coli* would be expected to undergo integration in the chosen host, and integrants would be selected using both the plasmid and the cassette resistance markers. Resolved cointegrants in which plasmid had been lost would be selected on sucrose as for *E. coli*. The plasmid should be lost quickly after resolution, as it cannot replicate.

REFERENCES

1. **Arigoni, F., F. Talabot, M. Peitsch, M. D. Edgerton, E. Meldrum, E. Allet, R. Fish, T. Jamotte, M. L. Curchod, and H. Loferer.** 1998. A genome-based approach for the identification of essential bacterial genes. Nat. Biotechnol. **16:**851–856.
2. **Benson, F. E., G. T. Illing, G. J. Sharples, and R. G. Lloyd.** 1988. Nucleotide sequencing of the *ruv* region of *Escherichia coli* K-12 reveals a LexA regulated operon encoding two genes. Nucleic Acids Res. **16:**1541–1549.
3. **Blattner, F. R., G. Plunkett III, C. A. Bloch, N. T. Perna, V. Burland, M. Riley, J. Collado-Vides, J. D. Glasner, C. K. Rode, G. F. Mayhew, J. Gregor, N. W. Davis, H. A. Kirkpatrick, M. A. Goeden, D. J. Rose, B. Mau, and Y. Shao.** 1997. The complete genome sequence of *Escherichia coli* K-12. Science **277:**1453–1474.
4. **Carrion, M., M. J. Gomez, R. Merchante-Schubert, S. Dongarra, and J. A. Ayala.** 1999. *mraW*, an essential gene at the *dcw* cluster of *Escherichia coli*, codes for a cytoplasmic protein with methyltransferase activity. Biochimie **81:**879–888.
5. **Cherepanov, P. P., and W. Wackernagel.** 1995. Gene disruption in *Escherichia coli*: Tc^R and Km^R cassettes with the option of Flp-catalyzed excision of the antibiotic-resistance determinant. Gene **158:**9–14.
6. **Dassain, M., A. Leroy, L. Colosetti, S. Carole, and J. P. Bouche.** 1999. A new essential gene of the ′minimal genome′ affecting cell division. Biochimie **81:**889–895.
7. **Datsenko, K. A., and B. L. Wanner.** 2000. One-step inactivation of chromosomal genes in *Escherichia coli* K-12 using PCR products. Proc. Natl. Acad. Sci. USA **97:**6640–6645.
8. **Hamilton, C. M., M. Aldea, B. K. Washburn, P. Babitzke, and S. R. Kushner.** 1989. New method for generating deletions and gene replacements in *Escherichia coli*. J. Bacteriol. **171:**4617–4622.
9. **Horton, R. M., H. D. Hunt, S. N. Ho, J. K. Pullen, and L. R. Pease.** 1989. Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension. Gene **77:**61–68.
10. **Liang, S. T., P. P. Dennis, and H. Bremer.** 1998. Expression of *lacZ* from the promoter of the *Escherichia coli spc* operon cloned into vectors carrying the W205 *trp-lac* fusion. J. Bacteriol. **180:**6090–6100.
11. **Link, A. J., D. Phillips, and G. M. Church.** 1997. Methods for generating precise deletions and insertions in the genome of wild-type *Escherichia coli*: application to open reading frame characterization. J. Bacteriol. **179:**6228–6237.
12. **Masters, M., T. Paterson, A. G. Popplewell, T. Owen-Hughes, J. H. Pringle, and K. J. Begg.** 1989. The effect of DnaA protein levels and the rate of initiation at *oriC* on transcription originating in the *ftsQ* and *ftsA* genes: in vivo experiments. Mol. Gen. Genet. **216:**475–483.
13. **Miller, J. M.** 1992. A short course in bacterial genetics: a laboratory manual and handbook for *Escherichia coli* and related bacteria. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
14. **Murphy, K. C.** 1998. Use of bacteriophage lambda recombination functions to promote gene replacement in *Escherichia coli*. J. Bacteriol. **180:**2063–2071.
15. **Outten, F. W., C. E. Outten, J. Hale, and T. V. O'Halloran.** 2000. Transcriptional activation of an *Escherichia coli* copper efflux regulon by the chromosomal MerR homologue, CueR. J. Biol. Chem. **275:**31024–31029.
16. **Posfai, G., V. Kolisnychenko, Z. Bereczki, and F. R. Blattner.** 1999. Markerless gene replacement in *Escherichia coli* stimulated by a double-strand break in the chromosome. Nucleic Acids Res. **27:**4409–4415.
17. **Sambrook, J., E. F. Fritsch, and T. Maniatis.** 1989. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
18. **Serres, M. H., S. Gopal, L. A. Nahum, P. Liang, T. Gaasterland, and M. Riley.** 2001. A functional update of the *Escherichia coli* K-12 genome. Genome Biol. **2.** [Online.] http://genomebiology.com/2001/2/9/research/0035./
19. **Simons, R. W., F. Houman, and N. Kleckner.** 1987. Improved single and multicopy *lac*-based cloning vectors for protein and operon fusions. Gene **53:**85–96.
20. **Yu, D., H. M. Ellis, E. C. Lee, N. A. Jenkins, N. G. Copeland, and D. L. Court.** 2000. An efficient recombination system for chromosome engineering in *Escherichia coli*. Proc. Natl. Acad. Sci. USA **97:**5978–5983.